Table 3 Oral pharmacokinetics of FLT3... | American Society of Hematology

Table 3

Oral pharmacokinetics of FLT3 inhibitors

Compound	Dose, mg/kg	C_max, μM	T_max, h	AUC_{0-24 h}, μM×h
AC220	10	3.8 ± 0.4	1.5 ± 0.9	35 ± 4
CEP-701	10	0.14 ± 0.06	0.92 ± 0.9	< 0.88†
MLN-518	10	0.081 ± 0.003	1.0 ± 0	0.28 ± 0.03
PKC-412*	10	0.77 ± 0.04	0.67 ± 0.3	2.5 ± 0.4
CGP-52421	From PKC-412*	2.3 ± 0.3	0.67 ± 0.3	8.4 ± 1
Sorafenib	10	12 ± 2	3.0 ± 3	240 ± 50
Sunitinib	10	0.32 ± 0.06	1.2 ± 0.8	1.1 ± 0.3

Compound	Dose, mg/kg	C_max, μM	T_max, h	AUC_{0-24 h}, μM×h
AC220	10	3.8 ± 0.4	1.5 ± 0.9	35 ± 4
CEP-701	10	0.14 ± 0.06	0.92 ± 0.9	< 0.88†
MLN-518	10	0.081 ± 0.003	1.0 ± 0	0.28 ± 0.03
PKC-412*	10	0.77 ± 0.04	0.67 ± 0.3	2.5 ± 0.4
CGP-52421	From PKC-412*	2.3 ± 0.3	0.67 ± 0.3	8.4 ± 1
Sorafenib	10	12 ± 2	3.0 ± 3	240 ± 50
Sunitinib	10	0.32 ± 0.06	1.2 ± 0.8	1.1 ± 0.3

Values shown are averages from 3 independent time courses (± SD).

PKC-412 and CGP-52421 were quantitated independently after dosing PKC-412.

The plasma concentration of CEP-701 was below the limit of detection at 24 hours.